AstraZeneca earnings fall amid patent protection losses

Posted: Updated:

LONDON (AP) - Anglo-Swedish drugmaker AstraZeneca says its net income and sales fell in the third quarter as it worked to make up for the loss of patent protection for major products such as Crestor and Seroquel XR.

Net income fell 32 percent to $686 million. Product sales slipped to $4.88 billion from $5.03 billion a year earlier.

AstraZeneca has been dealing with the loss of exclusivity on previous moneymakers like the cholesterol treatment Crestor and schizophrenia treatment Seroquel XR. Crestor sales fell 16 percent in the quarter, while Seroquel plunged 67 percent.

Sales of cancer drugs were up 18 percent. AstraZeneca repeatedly described oncology as one of its strengths as it fended off a takeover bid from Pfizer, which makes Viagra.

CEO Pascal Soriot says the performance "was in line with expectations."

Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

sorry to interrupt
your first 20 are free
Access to News 12 is free for Optimum, Comcast®, Time Warner® and Service ElectricSM customers.
Please enjoy 20 complimentary views of articles, photos, and videos during the next 30 days.
you have reached your 5 view limit
Access to News 12 is free for Optimum, Comcast®, Time Warner® and Service ElectricSM customers.
Please login, create an account or subscribe to continue enjoying News12.
Our sign-up page is undergoing maintenance and is not currently available. However, you will be given direct access to news12.com while we complete our upgrade.
When we are back up and running you will be prompted at that time to complete your sign in. Until then, enjoy the local news, weather, traffic and more that's "as local as local news gets."